Blueprint Medicines CEO Jeffrey Albers' 2019 pay slips 4% to $9.4M
Blueprint Medicines reports 2019 executive compensation
By ExecPay News
Published: April 29, 2020
Blueprint Medicines reported fiscal year 2019 executive compensation information on April 29, 2020.
In 2019, five executives at Blueprint Medicines received on average a compensation package of $4M, a 3% increase compared to previous year.
Average pay of disclosed executives at Blueprint Medicines
Jeffrey W. Albers, Chief Executive Officer, received $9.4M in total, which decreased by 4% compared to 2018. 62% of Albers' compensation, or $5.8M, was in option awards. Albers also received $379K in non-equity incentive plan, $590K in salary, $2.6M in stock awards, as well as $8.4K in other compensation.
For fiscal year 2019, the median employee pay was $360,897 at Blueprint Medicines. Therefore, the ratio of Jeffrey W. Albers' pay to the median employee pay was 26 to one.
Kathryn Haviland, Chief Operating Officer, received a compensation package of $3.1M, which increased by 19% compared to previous year. 55% of the compensation package, or $1.7M, was in option awards.
Tracey L. McCain, Chief Legal and Compliance Officer, earned $2.9M in 2019, a 10% increase compared to previous year.
Anthony Boral, Chief Medical Officer, received $2.6M in 2019, which decreases by 1% compared to 2018.
Michael Landsittel, Chief Financial Officer, earned $2M in 2019, a 13% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 29, 2020.